Cowen & Co. Downgrades Nektar Therapeutics to Market Perform
Cowen & Co. analyst Boris Peaker downgrades Nektar Therapeutics (NASDAQ:NKTR) from Outperform to Market Perform.
Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher
U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session.
Mid-Day Market Update: Markets Mixed; Nasdaq Drops Over 100 Points
The Nasdaq index turned lower midway through trading, losing more than 100 points on Monday.
50 Stocks Moving In Monday’s Mid-Day Session
Gainers
Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share.
Mid-Morning Market Update: Markets Open Higher; Crude Oil Dips 8%
U.S. stocks opened on a strong note this morning, with the Dow Jones gaining 300 points on Monday.
B of A Securities Downgrades Nektar Therapeutics to Underperform, Lowers Price Target to $6
B of A Securities analyst Greg Harrison downgrades Nektar Therapeutics (NASDAQ:NKTR) from Neutral to Underperform and lowers the price target from $18 to $6.
Bristol Myers Squibb And Nektar Announce Update On Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin In Combination With Opdivo; Companies to Unbind Trial And Perform No Additional Analyses For OS Endpoint
Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of
Oppenheimer Upgrades Nektar Therapeutics to Outperform, Announces $21 Price Target
Oppenheimer analyst Jay Olson upgrades Nektar Therapeutics (NASDAQ:NKTR) from Perform to Outperform and announces $21 price target.